Monte Rosa Therapeutics, Inc. reported financial results for the quarter ended March 31, 2026.
“On May 7, 2026, Monte Rosa Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2026.”
Monte Rosa Therapeutics, Inc. — fact timeline
Source-grounded facts extracted from Monte Rosa Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Monte Rosa Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters valued at $24.00 per share (effective 2026-01-08).
“On January 8, 2026, Monte Rosa Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters listed on Schedule 1 thereto (collectively, the “Underwriters”), related to an underwritten public offering (the “Offering”) of 11,125,000 shares (the “Underwritten Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a public offering price of $24.00 per share”
Jennifer Champoux changed role as Chief Operating Officer at Monte Rosa Therapeutics, Inc..
“On May 28, 2024, the Compensation, Nomination and Corporate Governance Committee of Board of Directors of Monte Rosa Therapeutics, Inc. (the “Company”) promoted Jennifer Champoux, the Company’s Chief People and Operations Officer, to serve as the Company’s Chief Operating Officer, effective as of May 28, 2024”
Monte Rosa Therapeutics, Inc. entered into Underwriting Agreement with TD Securities (USA) LLC, as representative of the several underwriters valued at approximately $96.7 million (effective 2024-05-15).
“On May 15, 2024, Monte Rosa Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, as representative of the several underwriters listed on Schedule 1 thereto (collectively, the “Underwriters”), related to an underwritten public offering”
Monte Rosa Therapeutics, Inc. reported financial results for the first quarter ending March 31, 2024.
“Monte Rosa Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.”
Owen Wallace resigned as Chief Scientific Officer at Monte Rosa Therapeutics, Inc..
“On April 29, 2024, Owen Wallace, the Chief Scientific Officer of Monte Rosa Therapeutics, Inc. (the "Company"), resigned from the Company effective May 17, 2024 (the “Effective Date”).”
Monte Rosa Therapeutics, Inc. reported financial results for full year and fourth quarter ended December 31, 2023.
“Monte Rosa Therapeutics, Inc. (the "Company") announced its financial results for the quarter and year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.